Next Article in Journal
Non-Invasive Spinal Cord Stimulation for Motor Rehabilitation of Patients with Spinal Muscular Atrophy Treated with Orphan Drugs
Previous Article in Journal
The Effectiveness of Atezolizumab in Metastatic Large Cell Neuroendocrine Carcinoma of the Lungs: Insights from the LANCE Pilot Study
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Biomedicines
Volume 12
Issue 6
10.3390/biomedicines12061160
biomedicines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Sex Differences in the Expression of Cardiac Remodeling and Inflammatory Cytokines in Patients with Obstructive Sleep Apnea and Atrial Fibrillation

by
Chun-Ting Shih
1,†,
Hui-Ting Wang
2,3,†,
Yung-Che Chen
4,
Ya-Ting Chang
5,
Pei-Ting Lin
1,
Po-Yuan Hsu
4,
Meng-Chih Lin
4,* and
Yung-Lung Chen
1,6,*
1
Division of Cardiology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung 833, Taiwan
2
Emergency Department, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 833, Taiwan
3
School of Medicine, College of Medicine, National Sun Yat-sen University, Kaohsiung 804, Taiwan
4
Division of Pulmonary & Critical Care Medicine, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung 833, Taiwan
5
Department of Neurology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung 833, Taiwan
6
Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Biomedicines 2024, 12(6), 1160; https://doi.org/10.3390/biomedicines12061160
Submission received: 28 April 2024 / Revised: 16 May 2024 / Accepted: 20 May 2024 / Published: 23 May 2024
(This article belongs to the Special Issue Pathogenesis, Diagnosis and Treatment of Cardiomyopathy and Cardiac Arrhythmias)
Browse Figures
Review Reports Versions Notes

Abstract

:
Although there is a link between obstructive sleep apnea (OSA) and atrial fibrillation (AF) and numerous investigations have examined the mechanism of AF development in OSA patients, which includes cardiac remodeling, inflammation, and gap junction-related conduction disorder, there is limited information regarding the differences between the sexes. This study analyzes the impact of sex differences on the expression of cardiac remodeling, inflammatory cytokines, and gap junctions in patients with OSA and AF. A total of 154 individuals diagnosed with sleep-related breathing disorders (SRBDs) were enrolled in the study and underwent polysomnography and echocardiography. Significant OSA was defined as an apnea–hypopnea index (AHI) of ≥15 per hour. Exosomes were purified from the plasma of all SRBD patients and incubated in HL-1 cells to investigate their effects on inflammatory cytokines and GJA1 expression. The differences in cardiac remodeling and expression of these biomarkers in both sexes were analyzed. Of the 154 enrolled patients, 110 patients were male and 44 patients were female. The LA sizes and E/e’ ratios of male OSA patients with concomitant AF were greater than those of control participants and those without AF (all p < 0.05). Meanwhile, female OSA patients with AF had a lower left ventricular ejection fraction than those OSA patients without AF and control subjects (p < 0.05). Regarding the expression of inflammatory cytokines and GJA1, the mRNA expression levels of GJA1 were lower and those of IL-1β were higher in those male OSA patients with AF than in those male OSA patients without AF and control subjects (p < 0.05). By contrast, mRNA expression levels of HIF-1α were higher in those female OSA patients with and without AF than in control subjects (p < 0.05). In conclusion, our study revealed sex-specific differences in the risk factors and biomarkers associated with AF development in patients with OSA.

1. Introduction

Obstructive sleep apnea (OSA) is a widely prevalent medical condition characterized by intermittent oxygen deprivation caused by recurrent upper airway obstruction during sleep [1]. Atrial fibrillation (AF), a common cardiac arrhythmia, has a significant global prevalence (2% to 4%) and is associated with heightened risks of stroke, heart failure (HF), cognitive impairment, depression, hospitalization, and mortality [2]. OSA is considered a potential risk factor for AF, implicated through mechanisms such as inflammatory responses, autonomic dysfunction, and negative thoracic pressure contributing to cardiac remodeling [3,4,5,6,7,8].
Sex differences in OSA and AF prevalence, clinical presentation, comorbidities, and pathophysiological mechanisms have been noted [9,10]. The prevalence of OSA is 27.3% in males, with a range of 9% to 86%, and 22.5% in females, with a range of 3.7% to 63.7%. Females often exhibit lower apnea–hypopnea index (AHI) scores but higher rates of symptomatic presentation, hypertension, and depression. Conversely, males show higher rates of diabetes and ischemic heart disease. Notably, HF with preserved ejection fraction (HFpEF) has a higher prevalence among females, while HF with reduced ejection fraction (HFrEF) is more prevalent in males [9,11].
AF incidence is higher in men, with female AF patients tending to be older and having higher rates of hypertension, valvular heart disease, and HFpEF but lower rates of coronary artery disease. Women with AF experience more severe symptoms and may have poorer responses to antiarrhythmic therapy or catheter ablation [12,13]. The pathophysiology of AF involves electrical and structural remodeling as well as autonomic neural regulation, with potential sex-specific differences [14,15].
Our study aimed to explore sex differences in individuals with concurrent OSA and AF, focusing on comorbidities, clinical presentation, cardiac remodeling, and pathophysiological mechanisms, as limited evidence currently exists in this area.

2. Materials and Methods

2.1. Patient Enrollment and Sample Management

This study enrolled individuals with sleep-related breathing disorders (SRBDs) in Kaohsiung Chang Gung Memorial Hospital between May 2019 and November 2022. Patients previously diagnosed and treated for OSA were excluded from the study. Other exclusions were made for individuals with acute infections, autoimmune disorders, malignancies, or those under 30. To mitigate confounding factors from severe systolic HF causing central sleep apnea and AF, patients with HFrEF were excluded from the analysis.
After enrollment, participants promptly underwent polysomnography (PSG), peripheral blood (PB) sampling, and echocardiography. In this investigation, patients did not undergo CPAP therapy or AF ablation until they completed all evaluations. Plasma derived from PB was utilized for exosome quantification and purification. Clinical features, including age, sex, body mass index (BMI), comorbidities, Epworth Sleepiness Scale (ESS) scores, PSG data, and echocardiographic parameters such as the dimensions of the aorta and the left atrium (LA), the thickness of the interventricular septum (IVS) and the left ventricular posterior wall (LVPW), the left ventricular end-diastolic and end-systolic volumes (LVEDV and LVESV), and left ventricular ejection fraction (LVEF) and E/e’ ratio were evaluated.
Before enrolling in the research, all participants were required to provide written informed consent. The research was approved by an institutional review board at Chang Gung Memorial Hospital (IRB numbers: 201801943B0 and 201801943B0C501~4) and complied with the tenets of the Declaration of Helsinki.

2.2. Study of Overnight PSG and Determination of SRBD Metrics

All study participants were subjected to PSG investigations overnight. Our prior studies provided in-depth descriptions of PSG methods [16,17,18]. The nightly PSG investigation was conducted at our hospital’s sleep department using a commercially available standardized suite (Sandman Elite, Mallinckrodt Inc., St. Louis, MO, USA). Skilled technicians identified, analyzed, and recorded sleep parameters according to predetermined criteria [19].
Apnea was characterized as the absence of nasal airflow for a minimum duration of 10 s, while hypopnea was operationally defined as a nasal airflow reduction of 30% or greater that persisted for a minimum of 10 s in conjunction with an arousal event or a decrease in pulse oximeter oxygen saturation surpassing 4% from the initial value. Significant OSA was operationally defined as an AHI equal to or greater than 15 events per hour accompanied by excessive daytime somnolence and sleep apneas. Patients who had an AHI of less than 15 per hour were deemed the control group in this study. The oxygen desaturation index (ODI) was determined by calculating the mean number of desaturation events per hour of sleep. Desaturation episodes were characterized by a reduction in oxygen saturation levels by 4% or more relative to the baseline value established before the event, with a minimum duration of 10 s.

2.3. Definition of AF, HF with Preserved or Mildly Reduced EF, and Echocardiographic Parameters

Using the 12-lead electrocardiogram (ECG) or 24 h ambulatory ECG, all study participants were evaluated, and clinical diagnoses of AF were made following the ACC/AHA/ESC 2016 criteria [20]. AF was characterized by the absence of p waves on an ECG and their replacement with fibrillatory waves. HFpEF or HF with a mildly reduced ejection fraction (HFmrEF) was defined as the presence of symptoms and/or signs of HF, an LVEF ≥ 50% (HFpEF) or 41–49% (HFmrEF), and objective evidence of cardiac anatomical and/or functional abnormalities that indicate the presence of left ventricular diastolic dysfunction or elevated left ventricular filling pressures, according to the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic HF [21].
Adhering to our established echocardiography protocol, we used a Sonos 7500 device (Live 3D Echo technology; Philips Medical Systems) to assess echocardiographic data [22,23,24]. The dimensions of the aorta, the LA, and the thickness of the IVS and the LVPW were measured. Additionally, LVEDV, LVESV, LVEF, and E/e’ were determined. The aorta’s diameter was assessed using M-mode echocardiography in the parasternal long-axis view, typically at the aortic root. LA size was assessed using two-dimensional echocardiography, measuring the anteroposterior and transverse diameters in the parasternal long-axis view. Using M-mode echocardiography with the parasternal long-axis view, the interventricular septum and the posterior wall of the left ventricle were assessed for thickness. Volume measurements were obtained using Simpson’s method, tracing the endocardial borders of the left ventricle in both end-diastolic and end-systolic phases from multiple echocardiographic views. LVEF was calculated using Teichholz’s or Simpson’s biplane method, assessing changes in left ventricular volume during the cardiac cycle. The E/e’, representing the ratio of E to the mean of the septal and lateral e’ velocities, was calculated by assessing transmitral Doppler (E wave) and tissue Doppler (e’ wave) velocities. As the peak velocity of early mitral inflow (E) was documented, tissue Doppler imaging facilitated the measurement of the early peak diastolic velocity (e’) at the septal and lateral mitral annulus. In patients with AF, the E/e’ ratio was determined according to our hospital’s standard echocardiography procedure, typically using a single representative beat assessment or index beat assessment, where E and e’ were selected to reflect an average value, as judged by an experienced cardiologist.

2.4. HL-1 Cell Culture

The HL-1 Cardiac Muscle Cell Line’s pooled primary cells were procured from SIGMA (SIGMA-ALDRICH Corp., St. Louis, MO, USA) and cultivated in a blend of Claycomb Basal Medium, following an established methodology [25]. HL-1 cells were meticulously seeded in a 6-well plate at a density of 4 × 105 cells/well.

2.5. Isolation, Purification, Quantification, and Incubation of Exosomes with HL-1 Cells

The process of isolating, purifying, and quantifying exosomes followed established methodologies [16,26,27,28]. PB samples were collected from individuals diagnosed with SRBDs. Subsequently, HL-1 cells underwent a 24 h treatment at 37 °C with exosomes obtained from patients diagnosed with both significant and non-significant OSA at a concentration of 10 µg/mL.

2.6. Real-Time Quantitative Reverse Transcriptase–Polymerase Chain Reaction Analysis (qRT-PCR) of mRNA Expression in HL-1 Cells

Following the aforementioned protocol, HL-1 cells were isolated, and RNA was extracted. Subsequently, complementary DNA (cDNA) was synthesized, and qRT-PCR analysis was performed [29,30]. The mRNA expression levels of inflammation-associated cytokines [Tumor necrosis factor (TNF)-α, Interleukin (IL)-1β, IL-6, and Transforming growth factor (TGF)-β], Hypoxia-inducible factor (HIF)-1α, and Gap junction alpha-1 (GJA1) were normalized using the internal control GAPDH to calculate the relative threshold cycle (ΔCt). The experimental procedure was duplicated to ensure the replication of each reaction.

2.7. Statistical Analysis

Our recent study found that OSA patients with AF had an LA size of 40.3 ± 6.4 mm. In contrast, OSA patients without AF had an LA size of 35.7 ± 4.6 mm [16]. The patient number ratio was calculated to be 1:4 when comparing individuals with and without AF. Based on a one-sided type I error rate of 0.025 and a power of 0.9, it was determined that a minimum of 100 OSA patients needed to be enrolled in the study. Out of these, 20 OSA patients had AF, and 80 did not have AF. Moreover, according to previous studies, the ratio of females to males was 1:4 [31,32]. The projected minimum number of female patients diagnosed with OSA and AF was 4, whereas the minimum number of male patients was 16.
All patients and subgroups are given detailed summaries. Quantitative data are displayed as percentages, means ± standard deviations, or medians with interquartile ranges. The Kruskal–Wallis H test was used to assess relationships between categorical variables in individuals with significant OSA and AF, those with significant OSA without AF, and those without significant OSA. For continuous data, appropriate statistical procedures, such as the Student’s t-test, the Mann–Whitney U test, and one-way ANOVA, were employed. The 2−ΔΔCt method was used to quantify relative changes in mRNA gene expression levels in HL-1 cells. All statistical analyses were performed using SPSS version 17.0 (SPSS, Chicago, IL, USA).

3. Results

3.1. Baseline Characteristics and Echocardiographic Data of Those OSA Patients with and without AF and Control Subjects

Between May 2019 and November 2022, we prospectively enrolled 154 patients with SRBDs. Among them, 110 (71.4%) were males, with an average age of 55 ± 11 years. One hundred and twenty-six (81.8%) had significant OSA with an AHI ≥ 15 per hour, and 28 (18.2%) did not. A summary of the distinctions between the OSA patients with and without AF and the control subjects is provided in Table 1. In brief, significant OSA was associated with an increased BMI, AHI, ODI, and duration of oxygen saturation (SpO2) < 90%, in addition to lowest and mean SpO2, compared to patients without OSA (all p < 0.05). The OSA patients with concomitant AF were older, a larger proportion of them were male, and there were more OSA patients with HF than OSA patients without AF and control subjects (all p < 0.05). Usage of medications, including beta-blockers, calcium channel blockers, antiarrhythmic drugs, and direct oral anticoagulants for AF treatment, was higher in patients with OSA and AF compared to OSA patients without AF and control subjects. Patients with and without clinically significant OSA exhibited comparable baseline characteristics, including sex, alcohol use, diabetes mellitus (DM), hypertension, HF, stroke, coronary artery disease, vital signs at enrollment, and ESS score. Regarding echocardiographic evaluation, OSA patients with comorbid AF had a larger LA size and E/e’ and a lower LVEF compared with OSA patients without AF and control subjects (all p < 0.05) (Table 1).

3.2. mRNA Gene Expression of HIF-1α and Inflammatory Cytokines in HL-1 Cells Treated with Exosomes Obtained from OSA Patients with and without AF and Control Subjects

To determine the mechanism and effect of intermittent hypoxemia events on atrial cardiomyocytes, exosomes obtained from OSA patients with and without AF, as well as control subjects, were used to treat HL-1 cells. The mRNA expression level of GJA1 was lower in those OSA patients with AF than in those without AF and control subjects (p < 0.05). OSA patients with AF also had higher mRNA expression levels of IL-1β than OSA patients without AF and higher mRNA expression levels of HIF-1α and TNF-α than control subjects (all p < 0.05). In addition, OSA patients without AF had higher HIF-1α expression than control subjects (p < 0.05). There was no difference in the mRNA expression of IL-6 and TGF-β among these three groups (Figure 1).

3.3. The Differences in Baseline Characteristics and Echocardiographic Data among Those Male OSA Patients with and without AF and Control Subjects

The differences among male OSA patients with and without AF and control subjects are summarized in Table 2. Male patients with significant OSA exhibited higher BMI, AHI, and ODI and lower lowest and mean SpO2 values (all p < 0.05). Those patients with coincident AF were older and included more patients with HF than male OSA patients without AF and control subjects (both p < 0.05). No differences were observed among the three groups in other baseline characteristics, except for the usage of medications for AF treatment, including beta-blockers, calcium channel blockers, antiarrhythmic drugs, and direct oral anticoagulants, which was higher in patients with OSA and AF compared to OSA patients without AF and control subjects. Male OSA patients with coincident AF had larger LA sizes and E/e’ ratios than those without AF and control subjects (all p < 0.05). Furthermore, male OSA patients with AF had lower LVEFs than control subjects (p < 0.05).

3.4. mRNA Gene Expression of HIF-1α and Inflammatory Cytokines in HL-1 Cells Treated with Exosomes Obtained from Those Male OSAS Patients with and without AF and Control Subjects

To assess the impact of intermittent hypoxemia episodes on atrial cardiomyocytes and the underlying mechanism, exosomes obtained from male patients with OSA and control subjects were utilized to treat HL-1 cells. The mRNA expression levels of GJA1 were lower and those of IL-1β were higher in the male OSA patients with AF than in the male OSA patients without AF and the control subjects (p < 0.05). Male OSA patients with AF had higher mRNA expression levels of TNF-α than control subjects (p < 0.05). The mRNA expression levels of HIF-1α, TGF-β, and IL-6 did not differ among the three groups (Figure 2).

3.5. The Differences in Baseline Characteristics and Echocardiographic Data among Those Female OSA Patients with and without AF and Control Subjects

The differences among female OSA patients with and without AF and control subjects are summarized in Table 3. Female patients with significant OSA had a higher AHI and ODI (both p < 0.05). Female patients with OSA and AF had a lower lowest SpO2 than the control subjects. There were no differences among the three groups in the other baseline characteristics. Female OSA patients with AF had a lower LVEF than the OSA patients without AF and the control subjects (p < 0.05). Additionally, female OSA patients with AF had a larger LA size than control subjects (p < 0.05).

3.6. mRNA Gene Expression of HIF-1α and Inflammatory Cytokines in HL-1 Cells Treated with Exosomes Obtained from Female Significant OSAS Patients with and without AF and Control Subjects

To assess the impact of intermittent hypoxemia episodes on atrial cardiomyocytes and the underlying mechanism, exosomes obtained from female patients with OSA and control subjects were utilized to treat HL-1 cells. The mRNA expression levels of HIF-1α were higher in the female OSA patients with and without AF than in the control subjects (p < 0.05). There was no difference in the mRNA expression of TNF-α, IL-1β, IL-6, TGF-β, and GJA1 among these three groups (Figure 3).

3.7. The Relationship between Age, BMI, Echocardiographic Parameters (LA Size, LVEF, and E/e’ Ratio), Gene Expression of Biomarkers (IL-1β and GJA1), and AF Occurrence in OSA Patients

A correlation analysis was performed to evaluate the relationship between age, BMI, and the results, including echocardiographic parameters (LA size, LVEF, and E/e’ ratio) and gene expression of biomarkers (IL-1β and GJA1), in OSA patients. The results showed no significant association between age, BMI, and these parameters (Supplementary Tables S1 and S2). The association between these parameters and AF occurrence in OSA patients after adjusting age and BMI was also analyzed. The results revealed that age and BMI did not significantly modulate the result (Supplementary Table S3).

4. Discussion

This study yielded several noteworthy findings. Firstly, individuals with OSA and AF were observed to be older and to have a higher prevalence of HF with preserved or mildly reduced EF, larger LA sizes, lower LVEF, and a higher E/e’ compared to those with OSA but without AF. Secondly, distinct sex-related variations were identified among individuals with both OSA and AF. Male OSA patients with AF were older and had a higher prevalence of HF with preserved or mildly reduced EF, larger LA sizes, and a higher E/e’ compared to their counterparts without AF. Conversely, female OSA patients with AF exhibited a notable decrease in LVEF compared to females without AF. Thirdly, concerning the potential mechanism underlying concurrent AF development in OSA patients, our study revealed that OSA patients with AF had lower expression of GJA1 compared to OSA patients without AF and control subjects. Additionally, OSA patients with AF demonstrated higher expression of IL-1β compared to OSA patients without AF and higher expression of TNF-α and HIF-1α compared to controls. Regarding the distinct expressions in male and female OSA patients, males with OSA and AF exhibited higher IL-1β and lower GJA1 expression than those without AF. Moreover, males with OSA and AF tended to have higher TNF-α and IL-1β expression and lower GJA1 expression than control subjects. Furthermore, females, irrespective of AF status, displayed higher expression of HIF-1α than control subjects, suggesting the potential impact of hypoxia on OSA development. However, no difference in HIF-1α expression was observed between female OSA patients with and without AF.
Previous studies have identified elderly individuals and those with comorbidities such as HF, DM, renal failure, and reduced diastolic function as predictors of incident AF in OSA patients [31,33,34]. Our study further corroborated these findings, highlighting that advanced age, HFpEF or HFmrEF, increased LA size, elevated E/e’, and decreased LVEF are associated with a heightened risk of AF in OSA patients. Increased E/e’ and LA size in our study signified augmented LA pressure and diastolic dysfunction [35], diastolic dysfunction, LA size, and LVEF having been established as crucial predictors of AF development in diverse cohort studies [16,36,37,38]. Our findings validate prior research by confirming that both age and a history of HFpEF or HFmrEF are predominant risk factors for AF in OSA patients. Notably, our study revealed that increased LA size and E/e’ pose a higher risk of AF development, especially in male OSA patients. Furthermore, a lower LVEF emerged as a risk factor for AF development in both males and females.
Several studies have shown that OSA has the potential to induce cardiac remodeling and systemic inflammation, which may contribute to the initiation and maintenance of AF [17,39,40,41,42,43]. Evidence is accumulating in the literature that the GJA1 gene is a crucial susceptibility factor for AF. A well-established AF locus, chromosome 6q22.31, houses the GJA1 gene [44]. Recent studies suggested that the single-nucleotide polymorphism (SNP) rs13216675, situated near the GJA1 gene on chromosome 6q22, was significantly associated with the risk of AF [45]. The GJA1 gene may be associated with abnormal atrial automaticity and involved in both the onset and persistence of AF [46]. Our study revealed a decreased expression of GJA1 in patients with co-existing AF and OSA compared to those OSA patients without AF. Connexin-43 (Cx43), a well-known connexin protein that affects cardiac conduction, is encoded by the GJA1 gene [47,48]. A previous study showed that Cx43 downregulation contributed to sympathetic AF by affecting intercellular channel conduction [46]. OSA-associated increased sympathetic tone, resulting in decreased expression of Cx43, may contribute to AF occurrence in OSA patients. Cx43 expression modulation could represent an innovative therapeutic strategy for AF. Additionally, our previous study demonstrated that the AHI and ODI in the non-rapid eye movement period (when the autonomic balance shifts from sympathetic to parasympathetic dominance) of OSA patients with AF exhibited a negative correlation with HL-1 cell GJA1 expression. This supports the notion that GJA1 likely has a significant impact on the progression of AF in individuals with OSA [16]. Interestingly, our study revealed the lowest GJA1 expression in OSA patients with AF and the highest expression in patients without OSA and AF in men. Still, there was no difference among the three groups in women. The assessment of heart rate variability indicated that women, compared to men of similar age, exhibited a dominance of vagal activity [49]. A recent study revealed that male patients with OSA exhibited higher LF/HF ratios compared to their female counterparts [50]. Further research should investigate the influence of autonomic dysfunction on the expression of GJA1 and the development of AF in OSA patients of different sexes.
Our investigation revealed higher levels of TNF-α and IL-1β expression in patients with both AF and OSA compared to individuals without OSA and AF. This difference was particularly significant in men but not in women. The development of AF, associated with pro-fibrotic processes, is linked to the inflammatory cascade. Well-documented biomarkers, such as TNF-α, IL-6, and IL-1β, have consistently been observed in both animal models and individuals affected by OSA [51,52]. Our previous study also demonstrated increased expression of HIF-1α, TNF-α, IL-6, and TGF-β in the intermittent hypoxia/reoxygenation condition [18]. Accumulating evidence supports the pivotal role of TNF-α and IL-1β in atrial remodeling, including structural, electrical, contractile, and autonomic remodeling, which may play a crucial role in the pathogenesis of AF. Moreover, prior research has indicated that TNF-α can influence the function of the sympathetic nervous system in isolated mouse atria and human atrial appendages [53,54]. Additionally, studies have shown that TNF-α affects the expression of Cx43, which plays a crucial role in regulating the conductance of Cx43 channels [55,56]. Additional research should delve into the intricate relationship between TNF-α, symptomatic tone, Cx43 expression, and the development of AF in males with OSA.
Hypoxemia may induce cardiac remodeling by influencing the expression of HIF-1 and 2 [42]. The repetitive deoxygenation and reoxygenation characteristics of OSA resemble ischemia–reperfusion injury, elevating reactive oxygen species production, vascular inflammation, and blood pressure [43]. These processes collectively contribute to myocardial injury and may lead to the development of AF in OSA patients. In the current study, HIF-1α expression was significantly elevated in female OSA patients with and without AF compared to the control group. This finding suggests that hypoxia may play a role in the pathogenesis of OSA in women. However, this study could not demonstrate a distinction in HIF-1α expression between females with and without AF who had OSA.
The enrollment of a limited number of patients, especially females, is a potential limitation of our study. With only four female patients diagnosed with both OSA and AF in our study, we may be limited in demonstrating the possible mechanisms of AF development in OSA patients. A previous Taiwanese study found that the number of female patients with significant OSA was significantly lower than that of male patients with significant OSA (male/female: 2.1-fold difference) [32]. Additionally, it reported that the risk of incident AF in male OSA patients was higher than in female patients (HR: 1.9) [31]. The crude risk ratio in male patients with OSA and AF compared to female patients was approximately 4-fold higher. We observed a similar trend in this study, with 19 male patients and 4 female patients diagnosed with significant OSA and AF (19/4 = 4.8). That trend explains why we enrolled a limited number of female patients with OSA and AF in this study. The sex distribution of OSA patients with AF in our study was similar to that reported in previous studies. Although a previous study using the US nationwide health insurance database showed that there was little difference between the incidence of arrhythmia in women with OSA compared with matched male patients [57], a separate cohort study conducted in Taiwan also demonstrated a lower prevalence of OSA and AF burden among women [58]. These findings suggest potential variations or discrepancies among different racial groups. This substantial sex difference underscores the importance of conducting further studies specifically focused on females, which could yield valuable insights into the underlying mechanisms. Additionally, a larger case–control study should be performed to validate this study’s main finding.

5. Conclusions

In conclusion, our study revealed sex-specific differences in the risk factors and biomarkers associated with AF development in patients with OSA. Further studies should be conducted to investigate the distinct pathophysiological mechanisms in males and females.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/biomedicines12061160/s1, Table S1: The correlation between age and echocardiographic parameters and also gene expression of biomarkers by linear regression; Table S2: The correlation between BMI and echocardiographic parameters and also gene expression of biomarkers by linear regression; Table S3: The predictor of AF occurrence in OSA patients before and after age and BMI adjustment by logistic regression.

Author Contributions

Y.-L.C. and M.-C.L. spearheaded the development and design of the study and made revisions to the paper. Y.-L.C., C.-T.S., P.-T.L. and P.-Y.H. gathered the research data and created the initial version of the text. Y.-T.C. and Y.-C.C. conducted clinical work and coordinated the collected data. Y.-L.C., H.-T.W. and C.-T.S. conducted the statistical analysis and wrote the text. Y.-L.C. and M.-C.L. oversaw and approved the clinical work and findings. All authors have read and agreed to the published version of the manuscript.

Funding

This study was supported by CMRPG8J0221, CMRPG8J0222, CMRPG8J0223, CMRPG8N0631, and CMRPG8K1391 grants from Kaohsiung Chang Gung Memorial Hospital, Taiwan, and by NMRPG8H0211 (MOST 107-2314-B-182A-151) and NMRPG8J0251 (MOST 108-2314-B-182A-137) grants from the Ministry of Science and Technology, Taiwan.

Institutional Review Board Statement

This study was approved by the Institutional Review Board of Chang Gung Memorial Hospital (IRB numbers: 201801943B0 and 201801943B0C501~4) and conformed to the guidelines set forth in the Declaration of Helsinki.

Informed Consent Statement

The participants’ written informed consent was obtained prior to the commencement of the study.

Data Availability Statement

The data underlying this article will be disclosed by the corresponding author upon reasonable request.

Acknowledgments

We express our gratitude to Hsin-Yi Chien, Chih-Yun Lin, Nien-Tzu Hsu, and the Biostatistics Center, Kaohsiung Chang Gung Memorial Hospital, for their invaluable contributions to this study’s statistical analysis.

Conflicts of Interest

There are no conflicts of interest to report by the authors. The funders refrained from any involvement in the studys design, data collection, analysis, interpretation, manuscript writing, or the determination to publish the findings.

References

  1. Somers, V.K.; White, D.P.; Amin, R.; Abraham, W.T.; Costa, F.; Culebras, A.; Daniels, S.; Floras, J.S.; Hunt, C.E.; Olson, L.J.; et al. Sleep apnea and cardiovascular disease: An American Heart Association/american College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council On Cardiovascular Nursing. In collaboration with the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health). Circulation 2008, 118, 1080–1111. [Google Scholar] [CrossRef] [PubMed]
  2. Ahmad, Y.; Lip, G.Y.; Lane, D.A. Recent developments in understanding epidemiology and risk determinants of atrial fibrillation as a cause of stroke. Can. J. Cardiol. 2013, 29, S4–S13. [Google Scholar] [CrossRef] [PubMed]
  3. Stevenson, I.H.; Roberts-Thomson, K.C.; Kistler, P.M.; Edwards, G.A.; Spence, S.; Sanders, P.; Kalman, J.M. Atrial electrophysiology is altered by acute hypercapnia but not hypoxemia: Implications for promotion of atrial fibrillation in pulmonary disease and sleep apnea. Heart Rhythm. 2010, 7, 1263–1270. [Google Scholar] [CrossRef] [PubMed]
  4. Iwasaki, Y.K.; Kato, T.; Xiong, F.; Shi, Y.F.; Naud, P.; Maguy, A.; Mizuno, K.; Tardif, J.C.; Comtois, P.; Nattel, S. Atrial fibrillation promotion with long-term repetitive obstructive sleep apnea in a rat model. J. Am. Coll. Cardiol. 2014, 64, 2013–2023. [Google Scholar] [CrossRef] [PubMed]
  5. Lo Martire, V.; Silvani, A.; Bastianini, S.; Berteotti, C.; Zoccoli, G. Effects of ambient temperature on sleep and cardiovascular regulation in mice: The role of hypocretin/orexin neurons. PLoS ONE 2012, 7, e47032. [Google Scholar] [CrossRef] [PubMed]
  6. Silvani, A.; Grimaldi, D.; Vandi, S.; Barletta, G.; Vetrugno, R.; Provini, F.; Pierangeli, G.; Berteotti, C.; Montagna, P.; Zoccoli, G.; et al. Sleep-dependent changes in the coupling between heart period and blood pressure in human subjects. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2008, 294, R1686–R1692. [Google Scholar] [CrossRef]
  7. Silvani, A.; Dampney, R.A. Central control of cardiovascular function during sleep. Am. J. Physiol. Heart Circ. Physiol. 2013, 305, H1683–H1692. [Google Scholar] [CrossRef]
  8. Abboud, F.; Kumar, R. Obstructive sleep apnea and insight into mechanisms of sympathetic overactivity. J. Clin. Investig. 2014, 124, 1454–1457. [Google Scholar] [CrossRef] [PubMed]
  9. Lam, C.S.P.; Arnott, C.; Beale, A.L.; Chandramouli, C.; Hilfiker-Kleiner, D.; Kaye, D.M.; Ky, B.; Santema, B.T.; Sliwa, K.; Voors, A.A. Sex differences in heart failure. Eur. Heart J. 2019, 40, 3859–3868c. [Google Scholar] [CrossRef]
  10. Lebek, S.; Hegner, P.; Tafelmeier, M.; Rupprecht, L.; Schmid, C.; Maier, L.S.; Arzt, M.; Wagner, S. Female Patients With Sleep-Disordered Breathing Display More Frequently Heart Failure With Preserved Ejection Fraction. Front. Med. 2021, 8, 675987. [Google Scholar] [CrossRef]
  11. Arzt, M.; Woehrle, H.; Oldenburg, O.; Graml, A.; Suling, A.; Erdmann, E.; Teschler, H.; Wegscheider, K.; Schla, H.F.I. Prevalence and Predictors of Sleep-Disordered Breathing in Patients With Stable Chronic Heart Failure: The SchlaHF Registry. JACC Heart Fail. 2016, 4, 116–125. [Google Scholar] [CrossRef] [PubMed]
  12. Linde, C.; Bongiorni, M.G.; Birgersdotter-Green, U.; Curtis, A.B.; Deisenhofer, I.; Furokawa, T.; Gillis, A.M.; Haugaa, K.H.; Lip, G.Y.H.; Van Gelder, I.; et al. Sex differences in cardiac arrhythmia: A consensus document of the European Heart Rhythm Association, endorsed by the Heart Rhythm Society and Asia Pacific Heart Rhythm Society. Europace 2018, 20, 1565–1565ao. [Google Scholar] [CrossRef] [PubMed]
  13. Piccini, J.P.; Simon, D.N.; Steinberg, B.A.; Thomas, L.; Allen, L.A.; Fonarow, G.C.; Gersh, B.; Hylek, E.; Kowey, P.R.; Reiffel, J.A.; et al. Differences in Clinical and Functional Outcomes of Atrial Fibrillation in Women and Men: Two-Year Results from the ORBIT-AF Registry. JAMA Cardiol. 2016, 1, 282–291. [Google Scholar] [CrossRef] [PubMed]
  14. Luo, X.; Yang, B.; Nattel, S. MicroRNAs and atrial fibrillation: Mechanisms and translational potential. Nat. Rev. Cardiol. 2015, 12, 80–90. [Google Scholar] [CrossRef] [PubMed]
  15. Odening, K.E.; Deiss, S.; Dilling-Boer, D.; Didenko, M.; Eriksson, U.; Nedios, S.; Ng, F.S.; Roca Luque, I.; Sanchez Borque, P.; Vernooy, K.; et al. Mechanisms of sex differences in atrial fibrillation: Role of hormones and differences in electrophysiology, structure, function, and remodelling. Europace 2019, 21, 366–376. [Google Scholar] [CrossRef] [PubMed]
  16. Chen, Y.L.; Chen, Y.C.; Chang, Y.T.; Wang, H.T.; Liu, W.H.; Chong, S.Z.; Lin, P.T.; Hsu, P.Y.; Su, M.C.; Lin, M.C. GJA1 Expression and Left Atrial Remodeling in the Incidence of Atrial Fibrillation in Patients with Obstructive Sleep Apnea Syndrome. Biomedicines 2021, 9, 1463. [Google Scholar] [CrossRef] [PubMed]
  17. Chen, Y.L.; Su, M.C.; Liu, W.H.; Wang, C.C.; Lin, M.C.; Chen, M.C. Influence and predicting variables of obstructive sleep apnea on cardiac function and remodeling in patients without congestive heart failure. J. Clin. Sleep. Med. 2014, 10, 57–64. [Google Scholar] [CrossRef]
  18. Chen, Y.L.; Chen, Y.C.; Wang, H.T.; Chang, Y.T.; Fang, Y.N.; Hsueh, S.; Liu, W.H.; Lin, P.T.; Hsu, P.Y.; Su, M.C.; et al. The Impact of Intermittent Hypoxemia on Left Atrial Remodeling in Patients with Obstructive Sleep Apnea Syndrome. Life 2022, 12, 148. [Google Scholar] [CrossRef]
  19. Redline, S.; Budhiraja, R.; Kapur, V.; Marcus, C.L.; Mateika, J.H.; Mehra, R.; Parthasarthy, S.; Somers, V.K.; Strohl, K.P.; Sulit, L.G.; et al. The scoring of respiratory events in sleep: Reliability and validity. J. Clin. Sleep. Med. 2007, 3, 169–200. [Google Scholar] [CrossRef]
  20. Kirchhof, P.; Benussi, S.; Kotecha, D.; Ahlsson, A.; Atar, D.; Casadei, B.; Castella, M.; Diener, H.C.; Heidbuchel, H.; Hendriks, J.; et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace 2016, 18, 1609–1678. [Google Scholar] [CrossRef]
  21. McDonagh, T.A.; Metra, M.; Adamo, M.; Gardner, R.S.; Baumbach, A.; Bohm, M.; Burri, H.; Butler, J.; Celutkiene, J.; Chioncel, O.; et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 2021, 42, 3599–3726. [Google Scholar] [CrossRef] [PubMed]
  22. Chen, Y.L.; Wang, H.T.; Chen, H.C.; Chai, H.T.; Lee, Y.W.; Liu, W.H. Localization of right ventricular non-apical lead position: Comparison of three-dimensional echocardiography, computed tomography, and fluoroscopic imaging. J. Int. Med. Res. 2021, 49, 300060521996159. [Google Scholar] [CrossRef] [PubMed]
  23. Liu, W.H.; Guo, B.F.; Chen, Y.L.; Tsai, T.H.; Fu, M.; Chua, S.; Chen, M.C. Right ventricular outflow tract pacing causes intraventricular dyssynchrony in patients with sick sinus syndrome: A real-time three-dimensional echocardiographic study. J. Am. Soc. Echocardiogr. 2010, 23, 599–607. [Google Scholar] [CrossRef] [PubMed]
  24. Abe, H.; Kosugi, S.; Ozaki, T.; Mishima, T.; Date, M.; Ueda, Y.; Uematsu, M.; Tamaki, S.; Yano, M.; Hayashi, T.; et al. Prognostic Impact of Echocardiographic Congestion Grade in HFpEF with and without Atrial Fibrillation. JACC Asia 2022, 2, 73–84. [Google Scholar] [CrossRef] [PubMed]
  25. Kuznetsov, A.V.; Javadov, S.; Sickinger, S.; Frotschnig, S.; Grimm, M. H9c2 and HL-1 cells demonstrate distinct features of energy metabolism, mitochondrial function and sensitivity to hypoxia-reoxygenation. Biochim. Biophys. Acta 2015, 1853, 276–284. [Google Scholar] [CrossRef] [PubMed]
  26. Tauro, B.J.; Greening, D.W.; Mathias, R.A.; Ji, H.; Mathivanan, S.; Scott, A.M.; Simpson, R.J. Comparison of ultracentrifugation, density gradient separation, and immunoaffinity capture methods for isolating human colon cancer cell line LIM1863-derived exosomes. Methods 2012, 56, 293–304. [Google Scholar] [CrossRef] [PubMed]
  27. Lydic, T.A.; Townsend, S.; Adda, C.G.; Collins, C.; Mathivanan, S.; Reid, G.E. Rapid and comprehensive ‘shotgun’ lipidome profiling of colorectal cancer cell derived exosomes. Methods 2015, 87, 83–95. [Google Scholar] [CrossRef] [PubMed]
  28. Huang, C.; Fisher, K.P.; Hammer, S.S.; Navitskaya, S.; Blanchard, G.J.; Busik, J.V. Plasma Exosomes Contribute to Microvascular Damage in Diabetic Retinopathy by Activating the Classical Complement Pathway. Diabetes 2018, 67, 1639–1649. [Google Scholar] [CrossRef]
  29. Hsu, P.Y.; Hsi, E.; Wang, T.M.; Lin, R.T.; Liao, Y.C.; Juo, S.H. MicroRNA let-7g possesses a therapeutic potential for peripheral artery disease. J. Cell. Mol. Med. 2017, 21, 519–529. [Google Scholar] [CrossRef]
  30. Nguyen, S.V.; Claycomb, W.C. Hypoxia regulates the expression of the adrenomedullin and HIF-1 genes in cultured HL-1 cardiomyocytes. Biochem. Biophys. Res. Commun. 1999, 265, 382–386. [Google Scholar] [CrossRef]
  31. Gami, A.S.; Hodge, D.O.; Herges, R.M.; Olson, E.J.; Nykodym, J.; Kara, T.; Somers, V.K. Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation. J. Am. Coll. Cardiol. 2007, 49, 565–571. [Google Scholar] [CrossRef]
  32. Chen, T.Y.; Kuo, T.B.J.; Chung, C.H.; Tzeng, N.S.; Lai, H.C.; Chien, W.C.; Yang, C.C.H. Age and sex differences on the association between anxiety disorders and obstructive sleep apnea: A nationwide case-control study in Taiwan. Psychiatry Clin. Neurosci. 2022, 76, 251–259. [Google Scholar] [CrossRef]
  33. Khamsai, S.; Junkrasien, C.; Limpawattana, P.; Chindaprasirt, J.; Senthong, V.; Boonsawat, W.; Sawanyawisuth, K. Prevalence and risk factors for persistent atrial fibrillation in obstructive sleep apnea. Sleep Sci. 2022, 15, 448–452. [Google Scholar] [CrossRef] [PubMed]
  34. Wang, H.; Li, J.; Gao, Y.; Chen, K.; Gao, Y.; Guo, J.; Shi, M.; Zou, X.; Xu, W.; Zhao, L.; et al. Prevalence and factors associated with atrial fibrillation in older patients with obstructive sleep apnea. BMC Geriatr. 2022, 22, 204. [Google Scholar] [CrossRef]
  35. Nagueh, S.F.; Smiseth, O.A.; Appleton, C.P.; Byrd, B.F., 3rd; Dokainish, H.; Edvardsen, T.; Flachskampf, F.A.; Gillebert, T.C.; Klein, A.L.; Lancellotti, P.; et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur. Heart J. Cardiovasc. Imaging 2016, 17, 1321–1360. [Google Scholar] [CrossRef] [PubMed]
  36. Tsang, T.S.; Gersh, B.J.; Appleton, C.P.; Tajik, A.J.; Barnes, M.E.; Bailey, K.R.; Oh, J.K.; Leibson, C.; Montgomery, S.C.; Seward, J.B. Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. J. Am. Coll. Cardiol. 2002, 40, 1636–1644. [Google Scholar] [CrossRef]
  37. Rosenberg, M.A.; Gottdiener, J.S.; Heckbert, S.R.; Mukamal, K.J. Echocardiographic diastolic parameters and risk of atrial fibrillation: The Cardiovascular Health Study. Eur. Heart J. 2012, 33, 904–912. [Google Scholar] [CrossRef] [PubMed]
  38. Cha, Y.M.; Redfield, M.M.; Shen, W.K.; Gersh, B.J. Atrial fibrillation and ventricular dysfunction: A vicious electromechanical cycle. Circulation 2004, 109, 2839–2843. [Google Scholar] [CrossRef] [PubMed]
  39. Dimitri, H.; Ng, M.; Brooks, A.G.; Kuklik, P.; Stiles, M.K.; Lau, D.H.; Antic, N.; Thornton, A.; Saint, D.A.; McEvoy, D.; et al. Atrial remodeling in obstructive sleep apnea: Implications for atrial fibrillation. Heart Rhythm. 2012, 9, 321–327. [Google Scholar] [CrossRef] [PubMed]
  40. Pepin, J.L.; Levy, P. Pathophysiology of cardiovascular risk in sleep apnea syndrome (SAS). Rev. Neurol. 2002, 158, 785–797. [Google Scholar]
  41. Kannel, W.B.; Benjamin, E.J. Current perceptions of the epidemiology of atrial fibrillation. Cardiol. Clin. 2009, 27, 13–24. [Google Scholar] [CrossRef] [PubMed]
  42. Prabhakar, N.R.; Semenza, G.L. Adaptive and maladaptive cardiorespiratory responses to continuous and intermittent hypoxia mediated by hypoxia-inducible factors 1 and 2. Physiol. Rev. 2012, 92, 967–1003. [Google Scholar] [CrossRef] [PubMed]
  43. Kohler, M.; Stradling, J.R. Mechanisms of vascular damage in obstructive sleep apnea. Nat. Rev. Cardiol. 2010, 7, 677–685. [Google Scholar] [CrossRef]
  44. Sinner, M.F.; Tucker, N.R.; Lunetta, K.L.; Ozaki, K.; Smith, J.G.; Trompet, S.; Bis, J.C.; Lin, H.; Chung, M.K.; Nielsen, J.B.; et al. Integrating genetic, transcriptional, and functional analyses to identify 5 novel genes for atrial fibrillation. Circulation 2014, 130, 1225–1235. [Google Scholar] [CrossRef]
  45. Chen, X.; Li, G.; Zhang, J.; Huang, X.; Ye, Z.; Zhao, Y. Association Between GJA1 rs13216675 T>C Polymorphism and Risk of Atrial Fibrillation: A Systematic Review and Meta-Analysis. Front. Cardiovasc. Med. 2020, 7, 585268. [Google Scholar] [CrossRef] [PubMed]
  46. Shu, C.; Huang, W.; Zeng, Z.; He, Y.; Luo, B.; Liu, H.; Li, J.; Xu, J. Connexin 43 is involved in the sympathetic atrial fibrillation in canine and canine atrial myocytes. Anatol. J. Cardiol. 2017, 18, 3–9. [Google Scholar] [CrossRef]
  47. Severs, N.J. Pathophysiology of gap junctions in heart disease. J. Cardiovasc. Electrophysiol. 1994, 5, 462–475. [Google Scholar] [CrossRef]
  48. Saffitz, J.E.; Laing, J.G.; Yamada, K.A. Connexin expression and turnover: Implications for cardiac excitability. Circ. Res. 2000, 86, 723–728. [Google Scholar] [CrossRef]
  49. Koenig, J.; Thayer, J.F. Sex differences in healthy human heart rate variability: A meta-analysis. Neurosci. Biobehav. Rev. 2016, 64, 288–310. [Google Scholar] [CrossRef]
  50. Buratti, L.; Rocchi, C.; Totaro, V.; Broggi, S.; Lattanzi, S.; Viticchi, G.; Falsetti, L.; Silvestrini, M. Sex-Related Differences in Polygraphic Parameters in a Population of Patients with Obstructive Sleep Apnea Syndrome. CNS Neurol. Disord. Drug Targets 2022, 21, 492–499. [Google Scholar] [CrossRef]
  51. Sheng, X.; Scherlag, B.J.; Yu, L.; Li, S.; Ali, R.; Zhang, Y.; Fu, G.; Nakagawa, H.; Jackman, W.M.; Lazzara, R.; et al. Prevention and reversal of atrial fibrillation inducibility and autonomic remodeling by low-level vagosympathetic nerve stimulation. J. Am. Coll. Cardiol. 2011, 57, 563–571. [Google Scholar] [CrossRef] [PubMed]
  52. Lim, D.C.; Brady, D.C.; Po, P.; Chuang, L.P.; Marcondes, L.; Kim, E.Y.; Keenan, B.T.; Guo, X.; Maislin, G.; Galante, R.J.; et al. Simulating obstructive sleep apnea patients’ oxygenation characteristics into a mouse model of cyclical intermittent hypoxia. J. Appl. Physiol. (1985) 2015, 118, 544–557. [Google Scholar] [CrossRef]
  53. Abadie, C.; Foucart, S.; Page, P.; Nadeau, R. Modulation of noradrenaline release from isolated human atrial appendages. J. Auton. Nerv. Syst. 1996, 61, 269–276. [Google Scholar] [CrossRef]
  54. Abadie, C.; Foucart, S.; Page, P.; Nadeau, R. Interleukin-1 beta and tumor necrosis factor-alpha inhibit the release of [3H]-noradrenaline from isolated human atrial appendages. Naunyn Schmiedebergs Arch. Pharmacol. 1997, 355, 384–389. [Google Scholar] [CrossRef] [PubMed]
  55. Fernandez-Cobo, M.; Gingalewski, C.; Drujan, D.; De Maio, A. Downregulation of connexin 43 gene expression in rat heart during inflammation. The role of tumour necrosis factor. Cytokine 1999, 11, 216–224. [Google Scholar] [CrossRef] [PubMed]
  56. George, S.A.; Calhoun, P.J.; Gourdie, R.G.; Smyth, J.W.; Poelzing, S. TNFalpha Modulates Cardiac Conduction by Altering Electrical Coupling between Myocytes. Front. Physiol. 2017, 8, 334. [Google Scholar] [CrossRef] [PubMed]
  57. Mokhlesi, B.; Ham, S.A.; Gozal, D. The effect of sex and age on the comorbidity burden of OSA: An observational analysis from a large nationwide US health claims database. Eur. Respir. J. 2016, 47, 1162–1169. [Google Scholar] [CrossRef]
  58. Lin, C.-H.; Liu, Y.-B.; Lin, L.-Y.; Huang, H.-C.; Ho, L.-T.; Wu, Y.-W.; Lai, L.-P.; Chen, W.-C.; Ho, Y.-L.; Yu, C.-C. Sex-based differences in obstructive sleep apnea and atrial fibrillation: Implication of atrial fibrillation burden. IJC Heart Vasc. 2024, 50, 101320. [Google Scholar] [CrossRef]
Biomedicines 12 01160 g001
Figure 1. The mRNA gene expression of HIF-1α (A) and inflammatory cytokines (B–F) was measured in HL-1 cells that were treated with exosomes obtained from OSA patients with and without AF, as well as from control subjects. The y-axis represents the fold changes in mRNA expression levels in HL-1 cells incubated with exosomes obtained from those OSA patients with AF (n = 23) and without AF (n = 103) compared to control subjects (n = 28). GJA1, gap junction alpha-1; HIF, hypoxia-inducible factor; IL, interleukin; OSA, obstructive sleep apnea; TGF, transforming growth factor; TNF, tumor necrosis factor.
Figure 1. The mRNA gene expression of HIF-1α (A) and inflammatory cytokines (B–F) was measured in HL-1 cells that were treated with exosomes obtained from OSA patients with and without AF, as well as from control subjects. The y-axis represents the fold changes in mRNA expression levels in HL-1 cells incubated with exosomes obtained from those OSA patients with AF (n = 23) and without AF (n = 103) compared to control subjects (n = 28). GJA1, gap junction alpha-1; HIF, hypoxia-inducible factor; IL, interleukin; OSA, obstructive sleep apnea; TGF, transforming growth factor; TNF, tumor necrosis factor.
Biomedicines 12 01160 g001
Biomedicines 12 01160 g002
Figure 2. The mRNA gene expression of HIF-1α (A) and inflammatory cytokines (B–F) in HL-1 cells treated with exosomes obtained from male significant OSAS patients with and without AF, as well as control subjects. The y-axis represents the fold changes in mRNA expression levels in HL-1 cells incubated with exosomes obtained from male OSA patients with AF (n = 19) and without AF (n = 78) compared to control subjects (n = 13). GJA1, gap junction alpha-1; HIF, hypoxia-inducible factor; IL, interleukin; OSAS, obstructive sleep apnea syndrome; TGF, transforming growth factor; TNF, tumor necrosis factor.
Figure 2. The mRNA gene expression of HIF-1α (A) and inflammatory cytokines (B–F) in HL-1 cells treated with exosomes obtained from male significant OSAS patients with and without AF, as well as control subjects. The y-axis represents the fold changes in mRNA expression levels in HL-1 cells incubated with exosomes obtained from male OSA patients with AF (n = 19) and without AF (n = 78) compared to control subjects (n = 13). GJA1, gap junction alpha-1; HIF, hypoxia-inducible factor; IL, interleukin; OSAS, obstructive sleep apnea syndrome; TGF, transforming growth factor; TNF, tumor necrosis factor.
Biomedicines 12 01160 g002
Biomedicines 12 01160 g003
Figure 3. The mRNA gene expression of HIF-1α (A) and inflammatory cytokines (B–F) in HL-1 cells treated with exosomes obtained from significant female OSA patients with and without AF, as well as control subjects. The y-axis represents the fold changes in mRNA expression levels in HL-1 cells incubated with exosomes derived from female OSA patients with AF (n = 4) and without AF (n = 25) compared to control subjects (n = 15). GJA1, gap junction alpha-1; HIF, hypoxia-inducible factor; IL, interleukin; OSAS, obstructive sleep apnea syndrome; TGF, transforming growth factor; TNF, tumor necrosis factor.
Figure 3. The mRNA gene expression of HIF-1α (A) and inflammatory cytokines (B–F) in HL-1 cells treated with exosomes obtained from significant female OSA patients with and without AF, as well as control subjects. The y-axis represents the fold changes in mRNA expression levels in HL-1 cells incubated with exosomes derived from female OSA patients with AF (n = 4) and without AF (n = 25) compared to control subjects (n = 15). GJA1, gap junction alpha-1; HIF, hypoxia-inducible factor; IL, interleukin; OSAS, obstructive sleep apnea syndrome; TGF, transforming growth factor; TNF, tumor necrosis factor.
Biomedicines 12 01160 g003
Table 1. Baseline characteristics of OSA patients with and without AF and control subjects.
Table 1. Baseline characteristics of OSA patients with and without AF and control subjects.
VariableOSA with AF
(n = 23)		OSA without AF
(n = 103)		Control
(n = 28)		p-Value
Age (years)61.4 (9.7) b54.3 (10.8) a53.3 (9.9) a0.009
Male sex19 (82.6) b78 (75.7) b13 (46.4) a0.004
BMI (kgs/m2)27.0 (3.3) b26.3 (3.3) b24.4 (3.2) a0.010
Alcohol consumption3 (13)19 (18.4)6 (21.4)0.737
AF type <0.001
Paroxysmal AF13 (56.5)00
Persistent AF10 (43.5)00
HTN12 (52.2)37 (35.9)4 (25.0)0.147
DM5 (21.7)8 (7.8)3 (10.7)0.160
HFpEF or HFmrEF3 (13.0)0 0 0.003
CAD2 (8.7)3 (2.9) 1 (3.6) 0.288
Stroke2 (8.7)4 (3.9)00.213
Vital signs at enrollment
Systolic blood pressure135.9 ± 17.1134.8 ± 14.4133.4 ± 16.80.852
Diastolic blood pressure79.1 ± 11.077.8 ± 10.075.5 ± 11.40.450
Heart rate78.4 ± 11.980.9 ± 12.184.3 ± 14.50.237
Medication
ACEI/ARB9 (39.1)30 (29.1)5 (17.9)0.241
Beta-blockers14 (60.9)25 (24.3)8 (28.6)0.003
Calcium channel blockers13 (56.5%)23 (22.3)6 (21.4)0.003
Diuretics2 (8.7)8 (7.8) 3 (10.7)0.883
Oral antidiabetic drugs3 (13)7 (6.8)3 (10.7)0.555
Statins5 (21.7)35 (34)8 (28.6)0.491
Antiarrhythmic drugs7 (30.4)00<0.001
Aspirin2 (8.7)13 (12.6)4 (14.3)0.824
P2Y12 inhibitors1 (4.3)7 (6.8)1 (3.6)0.769
Direct oral anticoagulants12 (52.2)00<0.001
PSG data
ESS8.0 (4.0–11.0)9.0 (6.0–12.0)9.0 (7.0–12.0)0.398
AHITST (/h)39.5 (26.0–63.5) b40.3 (24.8–57.0) b8.0 (4.5–11.2) a<0.001
AHIREM (/h)44.9 (37.7–59.1) b48.2 (32.0–63.2) b13.5 (9.8–21.0) a<0.001
AHINREM (/h)35.8 (23.3–63.9) b40.4 (21.9–56.9) b6.7 (3.6–9.4) a<0.001
ODITST (/h)30.4 (14.4–54.1) b26.2 (14.2–44.3) b4.7 (1.4–7.5) a<0.001
ODIREM (/h)37.9 (23.2–55.0) b41.0 (18.4–55.3) b9.6 (5.2–17.9) a<0.001
ODINREM (/h)31.6 (11.6–56.5) b23.3 (10.7–43.2) b3.9 (1.4–6.5) a<0.001
Lowest SpO2 (%)79.0 (62.0–88.0) b80.0 (73.0–85.0) b86 (85–90.7) a<0.001
Mean SpO2 (%)92.5 (91.5–94.6) b93.8 (92.2–94.9) b94.7 (93.3–95.9) a0.010
SpO2 < 90%7.6 (4.2–22.0) b6.0 (2.2–16.7) b1.7 (0.2–7.0) a0.008
Echocardiography
Aorta (mm)33.3 (4.3)32.5 (3.7)31.6 (4.5)0.337
LA (mm)40.3 (6.0) b 35.9 (4.4) a 34.2 (5.7) a<0.001
IVS (mm)11.8 (2.6)11.5 (1.7)11.0 (1.3)0.337
LVPW (mm)9.5 (1.9)9.2 (1.5)9.1 (1.3)0.590
LVEDV (mL)108.7 (41.3)110.8 (27.6)105.9 (23.0)0.787
LVESV (mL)42.2 (26.7)34.5 (17.3)29.8 (7.6)0.072
LVEF (%)63.9 (9.1) b69.2 (7.2) a71.4 (3.3) a0.001
E/e’10.4 (3.3) b8.3 (2.6) a9.0 (4.2) ab0.036
The data are presented as means (standard deviations), medians (interquartile ranges), or numbers (percentages). Different letters (a and b) in the columns denote statistically significant differences (p < 0.05, Bonferroni). AF, atrial fibrillation; AHI, apnea–hypopnea index; BMI, body mass index; CAD, coronary artery disease; DM, diabetes mellitus; ESS, Epworth Sleepiness Scale; HFpEF or HFmrEF, heart failure with preserved ejection fraction or heart failure with mildly reduced ejection fraction; HTN, hypertension; IVS, interventricular septum; LA, left atrium; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; LVEF, left ventricular ejection fraction; LVPW, left ventricular posterior wall; ODI, oxygen desaturation index; OSA, obstructive sleep apnea; PSG, polysomnography; SpO2, oxygen saturation.
Table 2. Baseline characteristics of male OSA patients with and without AF and control subjects.
Table 2. Baseline characteristics of male OSA patients with and without AF and control subjects.
Male (110)
VariableOSA with AF
(n = 19)		OSA without AF
(n = 78)		Control
(n = 13)		p-Value
Age (years)60.5 (9.5) b51.8 (10.4) a50.0 (9.9) a0.003
BMI (kgs/m2)26.7 (3.6) b26.6 (3.1) b23.6 (2.6) a0.005
Alcohol consumption3 (15.8)18 (23.1)5 (38.5)0.326
AF type <0.001
Paroxysmal AF11 (57.9)00
Persistent AF8 (42.1)00
HTN9 (47.4)27 (34.6)4 (30.8)0.549
DM3 (15.8)5 (6.4)1 (7.7)0.335
HFpEF or HFmrEF3 (15.8)0 0 0.006
CAD2 (10.5)2 (2.6) 0 0.203
Stroke2 (10.5)4 (5.1)00.400
Vital signs at enrollment
Systolic blood pressure134.1 ± 16.1135.6 ± 13.7134.2 ± 19.40.889
Diastolic blood pressure78.8 ± 10.879.1 ± 9.978.7 ± 11.90.988
Heart rate77.9 ± 11.082.5 ± 11.685.1 ± 15.00.200
Medication
ACEI/ARB7 (36.8)20 (25.6)3 (23.1)0.578
Beta-blockers12 (63.2)14 (17.9)3 (23.1)<0.001
Calcium channel blockers11 (57.9)16 (20.5)3 (23.1)0.004
Diuretics1 (5.3)6 (7.7)1 (7.7)0.934
Oral antidiabetic drugs2 (10.5)6 (7.7)2 (15.4)0.652
Statins4 (21.1)21 (26.9)2 (15.4)0.621
Antiarrhythmic drugs7 (36.8)00<0.001
Aspirin2 (10.5)11 (14.1)2 (15.4)0.903
P2Y12 inhibitors04 (5.1)00.427
Direct oral anticoagulants7 (36.8)00<0.001
PSG data
ESS8.0 (4.0–11.0)9.0 (6.0–12.0)9.0 (5.0–11.0)0.480
AHITST (/h)39.5 (26.0–63.0) b42.3 (25.7–58.3) b7.6 (3.4–10.6) a<0.001
AHIREM (/h)45.0 (37.7–58.5) b48.0 (31.0–62.9) b13.5 (5.7–19.8) a<0.001
AHINREM (/h)34.7 (23.3–63.9) b44.1 (23.2–58.4) b6.3 (3.2–8.7) a<0.001
ODITST (/h)29.9 (13.4–62.0) b27.5 (13.0–45.1) b4.6 (1.1–6.8) a<0.001
ODIREM (/h)39.1 (22.7–55.9) b41.1 (18.9–55.0) b7.3 (1.7–12.8) a<0.001
ODINREM (/h)31.2 (11.6–61.8) b29.3 (11.2–44.1) b4.5 (1.8–6.4) a<0.001
Lowest SpO2 (%)78.0 (62.5–87.0) b79.0 (73.0–84.0) b89 (85–91.5) a<0.001
Mean SpO2 (%)92.2 (91.0–94.9) b93.8 (92.3–95.0) ab94.6 (93.4–95.7) a0.035
SpO2 < 90%11.6 (4.2–26.4)5.9 (2.0–18.5)1.30 (0.25–7.5)0.054
Echocardiography
Aorta (mm)34.0 (4.1)33.5 (3.5)33.3 (5.2)0.881
LA (mm)40.0 (6.3) b 36.0 (4.7) a 36.4 (3.5) ab0.011
IVS (mm)11.7 (2.8)11.6 (1.8)11.4 (0.8)0.904
LVPW (mm)9.6 (2.1)9.3 (1.5)8.7 (0.6)0.446
LVEDV (mL)112.4 (44.0)114.5 (27.8)119.6 (21.6)0.851
LVESV (mL)43.7 (28.6)36.6 (19.0)33.2 (8.0)0.332
LVEF (%)64.0 (7.8) b68.3 (7.8) ab72.3 (4.1) a0.027
E/e’10.3 (3.5) b7.7 (2.1) a6.6 (2.2) a0.001
The data are presented as means (standard deviations), medians (interquartile ranges), or numbers (percentages). Different letters (a and b) in the columns denote statistically significant differences (p < 0.05, Bonferroni). AF, atrial fibrillation; AHI, apnea–hypopnea index; BMI, body mass index; CAD, coronary artery disease; DM, diabetes mellitus; ESS, Epworth Sleepiness Scale; HFpEF or HFmrEF, heart failure with preserved ejection fraction or heart failure with mildly reduced ejection fraction; HTN, hypertension; IVS, interventricular septum; LA, left atrium; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; LVEF, left ventricular ejection fraction; LVPW, left ventricular posterior wall; ODI, oxygen desaturation index; OSA, obstructive sleep apnea; PSG, polysomnography; SpO2, oxygen saturation.
Table 3. Baseline characteristics of female OSA patients with and without AF and control subjects.
Table 3. Baseline characteristics of female OSA patients with and without AF and control subjects.
Female (44)
VariableOSA with AF
(n = 4)		OSA without
(n = 25)		Control
(n = 15)		p-Value
Age (years)65.5 (11.1)62.0 (7.9)56.2 (9.2)0.069
BMI (kgs/m2)28.3 (0.9)25.2 (3.8)25.4 (3.6)0.270
Alcohol consumption01 (4)1 (6.7)0.834
AF type <0.001
Paroxysmal AF2 (50)00
Persistent AF2 (50)00
HTN3 (75.0)10 (40.0)3 (20.0)0.092
DM 2 (50.0)3 (12.0)2 (13.3)0.179
HFpEF or HFmrEF0 0 0 -
CAD0 1 (4.0) 1 (6.7)1.000
Stroke000-
Vital signs at enrollment
Systolic blood pressure144.5 ± 21.9132.2 ± 16.3132.8 ± 14.60.376
Diastolic blood pressure80.5 ± 13.374.1 ± 9.272.6 ± 10.50.386
Heart rate80.5 ± 17.675.9 ± 12.683.6 ± 14.40.243
Medication
ACEI/ARB2 (50)10 (40)2 (13.3)0.154
Beta-blockers2 (50)11 (44)5 (33.3)0.744
Calcium channel blockers2 (50)7 (28)3 (20)0.485
Diuretics1 (25)2 (8)2 (13.3)0.584
Oral antidiabetic drugs1 (25)1 (4)1 (6.7)0.302
Statins1 (25)14 (56)6 (40)0.392
Antiarrhythmic drugs000
Aspirin02 (8)2 (13.3)0.683
P2Y12 inhibitors1 (25)3 (12)1 (6.7)0.584
Direct oral anticoagulants1 (25)000.006
PSG data
ESS7.5 (1.7–11.0)9.0 (5.5–15.5)9.0 (8.0–12.0)0.541
AHITST (/h)50.1 (23.5–64.9) b31.0 (22.2–47.4) b9.6 (5.8–11.8) a<0.001
AHIREM (/h)41.3 (38.4) ab51.8 (33.1–63.3) b14.4 (9.9–23.1) a<0.001
AHINREM (/h)49.6 (21.1–64.9) b24.6 (21.3–44.4) b8.9 (4.7–9.6) a<0.001
ODITST (/h)35.4 (18.4–49.5) b23.6 (14.7–34.0) b4.9 (1.7–8.6) a<0.001
ODIREM (/h)34.1 (25.3) ab40.6 (13.9–55.3)b12.8 (6.8–22.9) a0.006
ODINREM (/h)36.0 (16.6–49.2) b20.8 (10.3–30.3) b3.3 (1.0–6.8) a<0.001
Lowest SpO2 (%)85.0 (79.0–88.0) b82.0 (74.2–86.7) ab86.0 (83.0–90.0) a0.021
Mean SpO2 (%)93.3 (92.6–94.1)93.7 (92.0–94.7)95.0 (93.3–96.0)0.249
SpO2 < 90%5.2 (2.9–6.3)6.0 (2.4–11.6)2.1 (0.1–5.8)0.162
Echocardiography
Aorta (mm)30.5 (4.7)29.8 (2.7)30.3 (3.7)0.874
LA (mm)42.0 (4.9) b35.6 (3.6) ab32.5 (6.5) a0.005
IVS (mm)12.0 (1.4)11.2 (1.4)10.6 (1.4)0.256
LVPW (mm)9.2 (0.9)8.9 (1.4)9.3 (1.7)0.759
LVEDV (mL)91.0 (19.7)101.0 (25.1)95.6 (18.7)0.636
LVESV (mL)34.7 (15.6)28.8 (10.0)27.2 (6.5)0.423
LVEF (%)63.7 (7.8) b71.6 (4.7) a70.8 (2.6) a0.012
E/e’10.9 (1.9)9.9 (3.2)10.2 (4.5)0.906
The data are presented as means (standard deviations), medians (interquartile ranges), or numbers (percentages). Different letters (a and b) in the columns denote statistically significant differences (p < 0.05, Bonferroni). AF, atrial fibrillation; AHI, apnea–hypopnea index; BMI, body mass index; CAD, coronary artery disease; DM, diabetes mellitus; ESS, Epworth Sleepiness Scale; HFpEF or HFmrEF, heart failure with preserved ejection fraction or heart failure with mildly reduced ejection fraction; HTN, hypertension; IVS, interventricular septum; LA, left atrium; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; LVEF, left ventricular ejection fraction; LVPW, left ventricular posterior wall; ODI, oxygen desaturation index; OSA, obstructive sleep apnea; PSG, polysomnography; SpO2, oxygen saturation.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Shih, C.-T.; Wang, H.-T.; Chen, Y.-C.; Chang, Y.-T.; Lin, P.-T.; Hsu, P.-Y.; Lin, M.-C.; Chen, Y.-L. Sex Differences in the Expression of Cardiac Remodeling and Inflammatory Cytokines in Patients with Obstructive Sleep Apnea and Atrial Fibrillation. Biomedicines 2024, 12, 1160. https://doi.org/10.3390/biomedicines12061160

AMA Style

Shih C-T, Wang H-T, Chen Y-C, Chang Y-T, Lin P-T, Hsu P-Y, Lin M-C, Chen Y-L. Sex Differences in the Expression of Cardiac Remodeling and Inflammatory Cytokines in Patients with Obstructive Sleep Apnea and Atrial Fibrillation. Biomedicines. 2024; 12(6):1160. https://doi.org/10.3390/biomedicines12061160

Chicago/Turabian Style

Shih, Chun-Ting, Hui-Ting Wang, Yung-Che Chen, Ya-Ting Chang, Pei-Ting Lin, Po-Yuan Hsu, Meng-Chih Lin, and Yung-Lung Chen. 2024. "Sex Differences in the Expression of Cardiac Remodeling and Inflammatory Cytokines in Patients with Obstructive Sleep Apnea and Atrial Fibrillation" Biomedicines 12, no. 6: 1160. https://doi.org/10.3390/biomedicines12061160

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop